AccuSafe guidewire vs traditional transseptal needle for X-ray-free transseptal puncture during AF ablation
Official title: Comparative Study on the Safety and Efficacy of Using AccuSafe Transseptal Guidewire Versus Traditional Transseptal Needle for Transseptal Puncture in non-or Free- Guidance
Run by Second Affiliated Hospital of Nanchang University · NCT07515040 · Data updated 2026-11-12
This tests whether the AccuSafe transseptal guidewire is safer and more effective than the traditional transseptal needle for people with atrial fibrillation undergoing catheter ablation guided by intracardiac echocardiography without X-rays.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Second Affiliated Hospital of Nanchang University Academic / other |
| Locations | 1 site (Nanchang, Jiangxi) |
| Status | Recruiting |
| Started | February 26, 2025 |
| Main results expected | February 26, 2027 |
| Study ends | February 26, 2027 |
| Registry record updated | April 7, 2026 |
| Trial ID | NCT07515040 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with diagnosed atrial fibrillation who are scheduled for radiofrequency catheter ablation and have normal fossa ovalis anatomy and can provide informed consent.
✕Probably not a fit
Patients with patent foramen ovale, atrial septal defects, prior septal closure, valve replacement, permanent pacemaker implantation, or those who require conversion to X‑ray guidance are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, single-center interventional trial will enroll 144 patients with atrial fibrillation scheduled for radiofrequency catheter ablation and randomize them 1:1 to transseptal puncture with the AccuSafe guidewire or a traditional transseptal needle. All procedures will be performed without fluoroscopy and guided by intracardiac echocardiography (ICE), with primary outcomes focused on procedural success and puncture-related complications. Safety endpoints include incidence of cardiac or vascular injury and need for conversion to X-ray guidance, while effectiveness endpoints include successful left atrial access and procedural workflow measures. Patients with abnormal fossa ovalis anatomy or prior septal repairs are excluded and intraoperative conversions to X-ray guidance will be treated as dropouts.
Why it matters
Potential benefit: If successful, the AccuSafe guidewire approach could reduce X-ray exposure and lower puncture-related complications, improving safety and procedural success for AF ablation patients.
How similar studies have gone: ICE-guided, X-ray-free transseptal techniques and dedicated guidewires have shown promising safety in small series, but randomized comparisons specifically of AccuSafe versus traditional needles are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: ① Age 18-75 years (inclusive); ② Clinically diagnosed with atrial fibrillation, indicated for radiofrequency ablation, and scheduled for catheter ablation; ③ Voluntarily agrees to participate in the trial and has signed informed consent; ⑤ Willing to comply with the trial requirements and complete the required follow-up. (All patients must have normal fossa ovalis anatomy confirmed by preoperative echocardiography; complex cases such as patent foramen ovale and atrial septal aneurysm are excluded) Exclusion Criteria: ① History of patent foramen ovale, atrial septal defect, post-atrial septal defect closure, post-valve replacement, or post-permanent pacemaker implantation; ② Intraoperative anatomical abnormalities requiring conversion to X-ray guidance-these patients will be withdrawn from the study and treated as dropouts.
Where it's running
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.